Maternal antibiotic use during childbirth tied to higher risk of autoimmune diseases in children

NewsGuard 100/100 Score

Children whose mothers have received antibiotic treatment during childbirth are more likely to develop autoimmune diseases compared to their counterparts, according to a recent registry-based study conducted at the University of Oulu, Finland, involving nearly 46,000 children. The most common autoimmune diseases in children include type 1 diabetes, celiac disease, and rheumatic diseases. However, the study found that administration of antibiotics during childbirth showed no association with allergic diseases or asthma in the child.

Antibiotic treatment given to mothers during delivery effectively prevents rare serious infections caused by Group B streptococcus in newborns, thereby reducing associated mortality. In Finland, antibiotics are administered to mothers during childbirth if Group B streptococcus is detected in the birth canal before delivery, and almost one in four women delivering vaginally receives antibiotic treatment.

The research findings play a crucial role in assessing the potential drawbacks of perinatal antibiotic use and investigating the underlying mechanisms of immune-related diseases. Previous knowledge indicated that antibiotics given to mothers during childbirth affect the development of the child's intestinal microbiota. The study supports the idea that a normal gut microbiota may have implications for a child's long-term health.

This is an observational study that does not directly establish a cause-and-effect relationship between the antibiotics given to mothers during childbirth and the child's later health. The result is a statistical association possibly influenced by other factors as well."

Sofia Ainonen, lead author of the article and doctoral researcher at the University of Oulu

According to Professor Terhi Ruuska, who led the study, the findings encourage the development of precise prevention methods for Group B streptococcus infections. One potential method could be a vaccine administered to mothers that does not impact the child's normal microbiota.

The study followed children born vaginally in Oulu University Hospital (OYS) and Oulaskangas hospital in Northern Ostrobothnia, Finland, between 2007 and 2018. The study utilised national registers from the National Institute for Health and Welfare, the Social Insurance Institution of Finland (Kela) and Statistics Finland, as well as high-quality electronic patient records from the hospitals in the OYS region, which provided comprehensive information on maternal antibiotic exposure.

The pre-approved version of the study was published in the American Journal of Obstetrics and Gynecology on February 16th.

Source:
Journal reference:

Ainonen, S., et al. (2024) Risk of Immune-related Diseases in Childhood after Intrapartum Antibiotic Exposure. ​​American Journal of Obstetrics and Gynecology. doi.org/10.1016/j.ajog.2024.02.020.

Comments

  1. Claire Cameron Claire Cameron Canada says:

    Lest we forget premmies and small for gestational age, neonates of Maternal DM, pre eclampsia , bacteremia with prolonged rupture of membranes had tragic peripartum mortality.We need multi centre trial of Gbs (strep)mums pon probiotics in pregnancy or breakthrough GBS if failed probiotic , Endpoints dyad maternal and  neonatal outcomes Claire cameronMD

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer